Ketamin Panpharma (Ketamine)

Ketamine is used in several clinical settings that involve the NMDA receptor pathway to achieve anesthesia, sedation, and analgesia.

• Induction and maintenance of general anesthesia: provides rapid onset dissociative anesthesia for surgical procedures.
• Procedural sedation: enables safe sedation for diagnostic or minor therapeutic interventions.
• Analgesia for acute pain: offers potent analgesic effect in peri‑operative or trauma settings.
• Treatment‑resistant depression (off‑label): may produce rapid antidepressant effects in selected patients under specialist supervision.

• Ketamine acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor, binding within the ion channel and reducing calcium influx. This blockade disrupts excitatory neurotransmission, leading to dissociative anesthesia and analgesia. Additional actions include interaction with opioid receptors, monoaminergic pathways, and voltage‑gated calcium channels, which contribute to its analgesic and antidepressant properties. The resultant cortical deactivation and altered thalamocortical signaling underlie the characteristic trance‑like state.

Ketamine may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Emergence delirium: transient confusion or hallucinations during recovery.
• Nausea and vomiting: gastrointestinal upset common after administration.
• Increased blood pressure: sympathetic stimulation causing transient hypertension.
• Salivation: excessive oral secretions.

Serious or Rare Side Effects

• Respiratory depression: severe hypoventilation requiring airway support.
• Cardiac arrhythmias: potential for tachyarrhythmias in susceptible patients.
• Severe allergic reaction: anaphylaxis with rash, bronchospasm, or hypotension.
• Urinary tract toxicity: chronic use may lead to cystitis.

When using Ketamin Panpharma, clinicians should observe several precautionary measures to ensure patient safety.

• Patient assessment: evaluate cardiovascular status and airway before administration.
• Dose titration: adjust dose gradually based on response and monitoring.
• Psychiatric monitoring: observe for emergence phenomena or dysphoric reactions.
• Contraindications: avoid in patients with known hypersensitivity to ketamine.
• Drug interactions: review concomitant medications that may potentiate CNS effects.
• Store below 25°C: keep in original container, protect from light and moisture.

Ketamine can interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Central nervous system depressants: concurrent use with benzodiazepines or opioids may cause profound respiratory depression.
• Sympathomimetic agents: may exacerbate hypertension and tachycardia.
• MAO inhibitors: increase risk of hypertensive crisis.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs: may enhance salivation and airway secretions.
• CYP450 substrates: ketamine is metabolized by CYP2B6 and CYP3A4; inhibitors can raise plasma levels.
• Alcohol: additive CNS effects require careful monitoring.